Glucagon and glucagon-like peptide receptors as drug targets

Current Pharmaceutical Design

Volumn 12, Issue 14, 2006, Pages 1731-1750

  Estall, J L ^a   Drucker, D J ^a  

^a TORONTO GENERAL HOSPITAL   (Canada)

Author keywords

Diabetes; G protein coupled receptors; GLP 1; GLP 2; Glucagon; Intestinal disease; PGDP; Proglucagon

Indexed keywords

(1 N ALPHA TRINITROPHENYLHISTIDINE 12 HOMOARGININE)GLUCAGON; 2 (BENZIMIDAZOL 2 YLTHIO) 1 (3,4 DIHYDROXYPHENYL) 1 ETHANONE; 4 HYDROXY 3 CYANOBENZOIC ACID(4 ISOPROPYLBENZYLOXY 3,5 DIMETHOXYMETHYLENE)HYDRAZIDE; 5 HYDROXYALKYL 4 PHENYLPYRIDINE DERIVATIVE; ALBUGON; ANTIDIABETIC AGENT; ANTISENSE OLIGONUCLEOTIDE; BAY 27 9955; BIARYL AMIDE DERIVATIVE; CJC 1131; ENZYME INHIBITOR; EXENDIN 4; G PROTEIN COUPLED RECEPTOR; GLUCAGON; GLUCAGON DERIVATIVE; GLUCAGON LIKE PEPTIDE; GLUCAGON LIKE PEPTIDE 1; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON LIKE PEPTIDE 2; HORMONE ANTAGONIST; L 168049; LIRAGLUTIDE; METFORMIN; NNC 25 2504; PROGLUCAGON; PROTEIN INHIBITOR; RECEPTOR BLOCKING AGENT; SKYRIN; SULFONYLUREA; UNCLASSIFIED DRUG; UNINDEXED DRUG;

APOPTOSIS; BLOOD BRAIN BARRIER; CALORIC INTAKE; CELL FUNCTION; CELL PROLIFERATION; CELL STIMULATION; CLINICAL TRIAL; CONTROLLED RELEASE FORMULATION; CRYPT CELL; DRUG INDUCED HEADACHE; DRUG PENETRATION; DRUG TARGETING; ENDOCRINE CELL; ENERGY ABSORPTION; ENERGY METABOLISM; ENTERITIS; EPITHELIUM CELL; FOOD INTAKE; GLUCAGON RELEASE; GLUCOGENESIS; GLUCOSE HOMEOSTASIS; HORMONE ACTION; HUMAN; INTESTINE CELL; INTESTINE MOTILITY; INTESTINE MUCOSA; KNOCKOUT MOUSE; LIVER METABOLISM; METABOLIC DISORDER; NAUSEA AND VOMITING; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PANCREAS ISLET BETA CELL; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECRETION; REVIEW; SHORT BOWEL SYNDROME; STOMACH EMPTYING; STRUCTURE ACTIVITY RELATION; UNITED STATES; WEIGHT GAIN;

AMINO ACID SEQUENCE; ANIMALS; DIABETES MELLITUS; GLUCAGON; GLUCAGON-LIKE PEPTIDES; HUMANS; HYPOGLYCEMIC AGENTS; MOLECULAR SEQUENCE DATA; OXYNTOMODULIN; RECEPTORS, GLUCAGON;

EID: 33646512858     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161206776873671     Document Type: Review

References (259)

1. Jiang G, Zhang BB. Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 2003; 284(4): E671-8.
2. Kieffer TJ, Habener JF. The glucagon-like peptides. Endocr Rev 1999; 20(6): 876-913.
3. Drucker DJ. Biological actions and therapeutic potential of the glucagon-like peptides. Gastroenterology 2002; 122(2): 531-44.
4. Mayo KE, Miller LJ, Bataille D, Dalle S, Goke B, Thorens B, et al. International Union of Pharmacology. XXXV. The Glucagon Receptor Family. Pharmacol Rev 2003; 55(1): 167-94.
5. Harmar AJ. Family-B G-protein-coupled receptors. Genome Biol 2001; 2(12): REVIEWS3013.
6. Pham VI, Sexton PM. Photoaffinity scanning in the mapping of the peptide receptor interface of class II G protein-coupled receptors. J Pept Sci 2004; 10(4): 179-203.
7. Unson CG, Wu CR, Jiang Y, Yoo B, Cheung C, Sakmar TP, et al. Roles of specific extracellular domains of the glucagon receptor in ligand binding and signaling. Biochemistry 2002; 41(39): 11795-803.
8. Waelbroeck M, Perret J, Vertongen P, Van Craenenbroeck M, Robberecht P. Identification of secretin, vasoactive intestinal peptide and glucagon binding sites: from chimaeric receptors to point mutations. Biochem Soc Trans 2002; 30(4): 437-41.
9. Lopez de Maturana R, Donnelly D. The glucagon-like peptide-1 receptor binding site for the N-terminus of GLP-1 requires polarity at Asp198 rather than negative charge. FEBS Lett 2002; 530(1-3):244-8.
10. Runge S, Gram C, Brauner-Osborne H, Madsen K, Knudsen LB, Wulff BS. Three distinct epitopes on the extracellular face of the glucagon receptor determine specificity for the glucagon amino terminus. J Biol Chem 2003; 278(30): 28005-10.
11. Runge S, Wulff BS, Madsen K, Brauner-Osborne H, Knudsen LB. Different domains of the glucagon and glucagon-like peptide-1 receptors provide the critical determinants of ligand selectivity. Br J Pharmacol 2003; 138(5): 787-94.
12. Lopez de Maturana R, Treece-Birch J, Abidi F, Findlay JB, Donnelly D. Met-204 and Tyr-205 are together important for binding GLP-1 receptor agonists but not their N-terminally truncated analogues. Protein Pept Lett 2004; 11(1): 15-22.
13. Rouille Y, Bianchi M, Irminger JC, Halban PA. Role of the prohormone convertase PC2 in the processing of proglucagon to glucagon. FEBS Lett 1997; 413(1): 119-23.
14. Brubaker PL, Drucker DJ. Structure-function of the glucagon receptor family of G protein-coupled receptors: the glucagon, GIP, GLP-1, and GLP-2 receptors. Receptors Channels 2002; 8(3-4): 179-88.
15. White CM. A review of potential cardiovascular uses of intravenous glucagon administration. J Clin Pharmacol 1999; 39(5): 442-7.
16. Farah AE. Glucagon and the circulation. Pharmacol Rev 1983; 35(3): 181-217.
17. Schwartz Sorensen S, Eiskjaer H, Orskov H, Bjerregaard Pedersen E. Effect of intravenous glucagon infusion on renal haemodynamics and renal tubular handling of sodium in healthy humans. Scand J Clin Lab Invest 1993; 53(1): 25-34.
18. Ahloulay M, Bouby N, Machet F, Kubrusly M, Coutaud C, Bankir L. Effects of glucagon on glomerular filtration rate and urea and water excretion. Am J Physiol 1992; 263(1 Pt 2): F24-36.
19. Patel GK, Whalen GE, Soergel KH, Wu WC, Meade RC. Glucagon effects on the human small intestine. Dig Dis Sci 1979; 24(7): 501-8.
20. Bernard SF, Thil MA, Groscolas R. Lipolytic and metabolic response to glucagon in fasting king penguins: phase II vs. phase III. Am J Physiol Regul Integr Comp Physiol 2003; 284(2): R444-54.
21. Heckemeyer CM, Barker J, Duckworth WC, Solomon SS. Studies of the biological effect and degradation of glucagon in the rat perifused isolated adipose cell. Endocrinology 1983; 113(1): 270-6.
22. Hippen AR. Glucagon as a potential therapy for ketosis and fatty liver. Vet Clin North Am Food Anim Pract 2000; 16(2): 267-82.
23. Hippen AR, She P, Young JW, Beitz DC, Lindberg GL, Richardson LF, et al. Alleviation of fatty liver in dairy cows with 14-day intravenous infusions of glucagon. J Dairy Sci 1999; 82(6): 1139-52.
24. Bertin E, Arner P, Bolinder J, Hagstrom-Toft E. Action of glucagon and glucagon-like peptide-1-(7-36) amide on lipolysis in human subcutaneous adipose tissue and skeletal muscle in vivo. J Clin Endocrinol Metab 2001; 86(3): 1229-34.
25. Gravholt CH, Moller N, Jensen MD, Christiansen JS, Schmitz O. Physiological levels of glucagon do not influence lipolysis in abdominal adipose tissue as assessed by microdialysis. J Clin Endocrinol Metab 2001; 86(5): 2085-9.
26. Herzig S, Long F, Jhala US, Hedrick S, Quinn R, Bauer A, et al. CREB regulates hepatic gluconeogenesis through the coactivator PGC-1. Nature 2001; 413(6852): 179-83.
27. Yoon JC, Puigserver P, Chen G, Donovan J, Wu Z, Rhee J, et al. Control of hepatic gluconeogenesis through the transcriptional coactivator PGC-1. Nature 2001; 413(6852): 131-8.
28. Burcelin R, Katz EB, Charron MJ. Molecular and cellular aspects of the glucagon receptor: role in diabetes and metabolism. Diabetes Metab 1996; 22(6): 373-96.
29. Landstedt-Hallin L, Adamson U, Lins PE. Oral glibenclamide suppresses glucagon secretion during insulin-induced hypoglycemia in patients with type 2 diabetes. J Clin Endocrinol Metab 1999; 84(9): 3140-5.
30. Segel SA, Paramore DS, Cryer PE. Hypoglycemia-associated autonomic failure in advanced type 2 diabetes. Diabetes 2002; 51(3): 724-33.
31. Cryer PE, Davis SN, Shamoon H. Hypoglycemia in diabetes. Diabetes Care 203; 26(6): 1902-12.
32. Dakin CL, Gunn I, Small CJ, Edwards CM, Hay DL, Smith DM, et al. Oxyntomodulin inhibits food intake in the rat. Endocrinology 2001; 142(10): 4244-50.
33. Dakin CL, Small CJ, Batterham RL, Neary NM, Cohen MA, Patterson M, et al. Peripheral oxyntomodulin reduces food intake and body weight gain in rats. Endocrinology 2004; 145(6): 2687-95.
34. Dakin CL, Small CJ, Park AJ, Seth A, Ghatei MA, Bloom SR. Repeated ICV administration of oxyntomodulin causes a greater reduction in body weight gain than in pair-fed rats. Am J Physiol Endocrinol Metab 2002; 283(6): E1173-7.
35. Baggio LL, Huang Q, Brown TJ, Drucker DJ. Oxyntomodulin and glucagon-like peptide-1 differentially regulate murine food intake and energy expenditure. Gastroenterology 2004; 127(2): 546-58.
36. Cohen MA, Ellis SM, Le Roux CW, Batterham RL, Park A, Patterson M, et al. Oxyntomodulin suppresses appetite and reduces food intake in humans. J Clin Endocrinol Metab 2003; 88(10): 4696-701.
37. Larsson H, Ahren B. Islet dysfunction in insulin resistance involves impaired insulin secretion and increased glucagon secretion in postmenopausal women with impaired glucose tolerance. Diabetes Care 2000; 23(5): 650-7.
38. Dinneen S, Alzaid A, Turk D, Rizza R. Failure of glucagon suppression contributes to postprandial hyperglycaemia in IDDM. Diabetologia 1995; 38(3): 337-43.
39. Unger RH. Role of glucagon in the pathogenesis of diabetes: the status of the controversy. Metabolism 1978; 27(11): 1691-709.
40. Unger RH. Glucagon physiology and pathophysiology in the light of new advances. Diabetologia 1985; 28(8): 574-8.
41. Shah P, Basu A, Basu R, Rizza R. Impact of lack of suppression of glucagon on glucose tolerance in humans. Am J Physiol 1999; 277(2 Pt 1): E283-90.
42. Shah P, Vella A, Basu A, Basu R, Schwenk WF, Rizza RA. Lack of suppression of glucagon contributes to postprandial hyperglycemia in subjects with type 2 diabetes mellitus. J Clin Endocrinol Metab 2000; 85(11): 4053-9.
43. Johnson DG, Goebel CU, Hruby VJ, Bregman MD, Trivedi D. Hyperglycemia of diabetic rats decreased by a glucagon receptor antagonist. Science 1982; 215(4536): 1115-6.
44. Hagopian WA, Tager HS, Gysin B, Trivedi D, Hruby VJ. Interactions of glucagon and glucagon analogs with isolated canine hepatocytes. J Biol Chem 1987; 262(32): 15506-13.
45. Gysin B, Johnson DG, Trivedi D, Hruby VJ. Synthesis of two glucagon antagonists: receptor binding, adenylate cyclase, and effects on blood plasma glucose levels. J Med Chem 1987; 30(8): 1409-15.
46. Gysin B, Trivedi D, Johnson DG, Hruby VJ. Design and synthesis of glucagon partial agonists and antagonists. Biochemistry 1986; 25(25): 8278-84.
47. Hruby VJ, Gysin B, Trivedi D, Johnson DG. New glucagon analogues with conformational restrictions and altered amphiphilicity: effects on binding, adenylate cyclase and glycogenolytic activities. Life Sci 1993; 52(10): 845-55.
48. Ahn JM, Gitu PM, Medeiros M, Swift JR, Trivedi D, Hruby VJ. A new approach to search for the bioactive conformation of glucagon: positional cyclization scanning. J Med Chem 2001; 44(19): 3109-16.
49. Ahn JM, Medeiros M, Trivedi D, Hruby VJ. Development of potent truncated glucagon antagonists. J Med Chem 2001; 44(9): 1372-9.
50. Streicher R, Wagner K, Vettermann R, Potterat O. Identification and characterisation of a novel peptidic glucagon receptor antagonist. In: European Association for the Study of Diabetes (EASD), 40th Annual Meeting; 2004 Sept. 5-9; Munich, Germany 2004.
51. Brand CL, Jorgensen PN, Knigge U, Warberg J, Svendsen I, Kristensen JS, et al. Role of glucagon in maintenance of euglycemia in fed and fasted rats. Am J Physiol 1995; 269(3 Pt 1): E469-77.
52. Brand CL, Jorgensen PN, Svendsen I, Holst JJ. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 1996; 45(8): 1076-83.
53. Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 1994; 37(10): 985-93.
54. Djuric SW, Grihalde N, Lin CW. Glucagon receptor antagonists for the treatment of type II diabetes: current prospects. Curr Opin Investig Drugs 2002; 3(11): 1617-23.
55. Madsen P, Knudsen LB, Wiberg FC, Carr RD. Discovery and structure-activity relationship of the first non-peptide competitive human glucagon receptor antagonists. J Med Chem 1998; 41(26): 5150-7.
56. Cascieri MA, Koch GE, Ber E, Sadowski SJ, Louizides D, de Laszlo SE, et al. Characterization of a novel, non-peptidyl antagonist of the human glucagon receptor. J Biol Chem 1999; 274(13): 8694-7.
57. Chang LL, Sidler KL, Cascieri MA, de Laszlo S, Koch G, Li B, et al. Substituted imidazoles as glucagon receptor antagonists. Bioorg Med Chem Lett 2001; 11(18): 2549-53.
58. Ling A, Hong Y, Gonzalez J, Gregor V, Polinsky A, Kuki A, et al. Identification of alkylidene hydrazides as glucagon receptor antagonists. J Med Chem 2001; 44(19): 3141-9.
59. Ling A, Plewe M, Gonzalez J, Madsen P, Sams CK, Lau J, et al. Human glucagon receptor antagonists based on alkylidene hydrazides. Bioorg Med Chem Lett 2002; 12(4): 663-6.
60. Madsen P, Ling A, Plewe M, Sams CK, Knudsen LB, Sidelmann UG, et al. Optimization of alkylidene hydrazide based human glucagon receptor antagonists. Discovery of the highly potent and orally available 3-cyano-4-hydroxybenzoic acid [1-(2, 3, 5, 6-tetramethylbenzyl)-1H-indol-4-ylmethylene]hydrazide. J Med Chem 2002; 45(26): 5755-75.
61. Petersen KF, Sullivan JT. Effects of a novel glucagon receptor antagonist (Bay 27-9955) on glucagon-stimulated glucose production in humans. Diabetologia 2001; 44(11): 2018-24.
62. Ladouceur GH, Cook JH, Doherty EM, Schoen WR, MacDougall ML, Livingston JN. Discovery of 5-hydroxyalkyl-4-phenylpyridines as a new class of glucagon receptor antagonists. Bioorg Med Chem Lett 2002; 12(3): 461-4.
63. Kurukulasuriya R, Sorensen BK, Link JT, Patel JR, Jae HS, Winn MX, et al. Biaryl amide glucagon receptor antagonists. Bioorg Med Chem Lett 2004; 14(9): 2047-50.
64. Parker JC, McPherson RK, Andrews KM, Levy CB, Dubins JS, Chin JE, et al. Effects of skyrin, a receptor-selective glucagon antagonist, in rat and human hepatocytes. Diabetes 2000; 49(12): 2079-86.
65. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem Biophys Res Commun 2002; 290(2): 839-43.
66. Gelling RW, Du XQ, Dichmann DS, Romer J, Huang H, Cui L, et al. Lower blood glucose, hyperglucagonemia, and pancreatic alpha cell hyperplasia in glucagon receptor knockout mice. Proc Natl Acad Sci USA 2003; 100(3): 1438-43.
67. Dallas-Yang Q, Shen X, Strowski M, Brady E, Saperstein R, Gibson RE, et al. Hepatic glucagon receptor binding and glucose-lowering in vivo by peptidyl and non-peptidyl glucagon receptor antagonists. Eur J Pharmacol 2004; 501(1-3): 225-34.
68. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, et al. Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 2004; 53(2): 410-7.
69. Sloop KW, Cao JX, Siesky AM, Zhang HY, Bodenmiller DM, Cox AL, et al. Hepatic and glucagon-like peptide-1-mediated reversal of diabetes by glucagon receptor antisense oligonucleotide inhibitors. J Clin Invest 2004; 113(11): 1571-81.
70. Creutzfeldt WO, Kleine N, Willms B, Orskov C, Holst JJ, Nauck MA. Glucagonostatic actions and reduction of fasting hyperglycemia by exogenous glucagon-like peptide I(7-36) amide in type I diabetic patients. Diabetes Care 1996; 19(6): 580-6.
71. Levetan C, Want LL, Weyer C, Strobel SA, Crean J, Wang Y, et al. Impact of pramlintide on glucose fluctuations and postprandial glucose, glucagon, and triglyceride excursions among patients with type 1 diabetes intensively treated with insulin pumps. Diabetes Care 2003; 26(1): 1-8.
72. Blache P, Kervran A, Le-Nguyen D, Dufour M, Cohen-Solal A, Duckworth W, et al. Endopeptidase from rat liver membranes, which generates miniglucagon from glucagon. J Biol Chem 1993; 268(29): 21748-53.
73. Dalle S, Smith P, Blache P, Le-Nguyen D, Le Brigand L, Bergeron F, et al. Miniglucagon (glucagon 19-29), a potent and efficient inhibitor of secretagogue-induced insulin release through a Ca2+ pathway. J Biol Chem 1999; 274(16): 10869-76.
74. Mallat A, Pavoine C, Dufour M, Lotersztajn S, Bataille D, Pecker F. A glucagon fragment is responsible for the inhibition of the liver Ca2+ pump by glucagon. Nature 1987; 325(6105): 620-2.
75. Pavoine C, Brechler V, Kervran A, Blache P, Le-Nguyen D, Laurent S, et al. Miniglucagon [glucagon-(19-29)] is a component of the positive inotropic effect of glucagon. Am J Physiol 1991; 260(5 Pt 1): C993-9.
76. Sauvadet A, Rohn T, Pecker F, Pavoine C. Synergistic actions of glucagon and miniglucagon on Ca2+ mobilization in cardiac cells. Circ Res 1996; 78(1): 102-9.
77. Lotersztajn S, Pavoine C, Brechler V, Roche B, Dufour M, Le-Nguyen D, et al. Glucagon-(19-29) exerts a biphasic action on the liver plasma membrane Ca2+ pump which is mediated by G proteins. J Biol Chem 1990; 265(17): 9876-80.
78. Dalle S, Longuet C, Costes S, Broca C, Faruque O, Fontes G, et al. Glucagon promotes cAMP-response element-binding protein phosphorylation via activation of ERK1/2 in MIN6 cell line and isolated islets of Langerhans. J Biol Chem 2004; 279(19): 20345-55.
79. Dalle S, Fontes G, Lajoix AD, LeBrigand L, Gross R, Ribes G, et al. Miniglucagon (glucagon 19-29): a novel regulator of the pancreatic islet physiology. Diabetes 2002; 51(2): 406-12.
80. Ghatei MA, Uttenthal LO, Christofides ND, Bryant MG, Bloom SR. Molecular forms of human enteroglucagon in tissue and plasma: plasma responses to nutrient stimuli in health and in disorders of the upper gastrointestinal tract. J Clin Endocrinol Metab 1983; 57(3): 488-95.
81. Roberge JN, Brubaker PL. Secretion of proglucagon-derived peptides in response to intestinal luminal nutrients. Endocrinology 1991; 128(6): 3169-74.
82. Rocca AS, Brubaker PL. Stereospecific effects of fatty acids on proglucagon-derived peptide secretion in fetal rat intestinal cultures. Endocrinology 1995; 136(12): 5593-9.
83. Reimer RA, McBurney MI. Dietary fiber modulates intestinal proglucagon messenger ribonucleic acid and postprandial secretion of glucagon-like peptide-1 and insulin in rats. Endocrinology 1996; 137(9): 3948-56.
84. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology 1999; 117(1): 99-105.
85. Rocca AS, LaGreca J, Kalitsky J, Brubaker PL. Monounsaturated fatty acid diets improve glycemic tolerance through increased secretion of glucagon-like peptide-1. Endocrinology 2001; 142(3): 1148-55.
86. Roberge JN, Brubaker PL. Regulation of intestinal proglucagonderived peptide secretion by glucose-dependent insulinotropic peptide in a novel enteroendocrine loop. Endocrinology 1993; 133(1): 233-40.
87. Hansen L, Hartmann B, Bisgaard T, Mineo H, Jorgensen PN, Holst JJ. Somatostatin restrains the secretion of glucagon-like peptide-1 and -2 from isolated perfused porcine ileum. Am J Physiol Endocrinol Metab 2000; 278(6): E1010-8.
88. Roberge JN, Gronau KA, Brubaker PL. Gastrin-releasing peptide is a novel mediator of proximal nutrient-induced proglucagon-derived peptide secretion from the distal gut. Endocrinology 1996; 137(6): 2383-8.
89. Rocca AS, Brubaker PL. Role of the vagus nerve in mediating proximal nutrient-induced glucagon-like peptide-1 secretion. Endocrinology 1999; 140(4): 1687-94.
90. Brubaker PL, Anini Y. Direct and indirect mechanisms regulating secretion of glucagon-like peptide-1 and glucagon-like peptide-2. Can J Physiol Pharmacol 2003; 81(11): 1005-12.
91. Drucker DJ. Glucagon-like peptides. Diabetes 1998; 47(2): 159-69.
92. Drucker DJ. Minireview: the glucagon-like peptides. Endocrinology 2001; 142(2): 521-7.
93. Drucker DJ. Enhancing incretin action for the treatment of type 2 diabetes. Diabetes Care 2003; 26(10): 2929-40.
94. Baggio LL, Drucker DJ. Glucagon-Like Peptide 1(GLP-1) and Glucagon-Like Peptide-2 (GLP-2). Bailliere's Best Practice and Research in Clinical Endocrinology and Metabolism 2004; in press.
95. Farilla L, Hui H, Bertolotto C, Kang E, Bulotta A, Di Mario U, et al. Glucagon-like peptide-1 promotes islet cell growth and inhibits apoptosis in Zucker diabetic rats. Endocrinology 2002; 143(11): 4397-408.
96. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagon-like peptide-1 receptor signaling modulates beta cell apoptosis. J Biol Chem 2003; 278(1): 471-8.
97. Farilla L, Bulotta A, Hirshberg B, Li Calzi S, Khoury N, Noushmehr H, et al. Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets. Endocrinology 2003; 144(12): 5149-58.
98. Hui H, Nourparvar A, Zhao X, Perfetti R. Glucagon-like peptide-1 inhibits apoptosis of insulin-secreting cells via a cyclic 5′-adenosine monophosphate-dependent protein kinase A- and a phosphatidylinositol 3-kinase-dependent pathway. Endocrinology 2003; 144(4): 1444-55.
99. Buteau J, El-Assaad W, Rhodes CJ, Rosenberg L, Joly E, Prentki M. Glucagon-like peptide-1 prevents beta cell glucolipotoxicity. Diabetologia 2004; 47(5): 806-15.
100. Bullock BP, Heller RS, Habener JF. Tissue distribution of messenger ribonucleic acid encoding the rat glucagon-like peptide-1 receptor. Endocrinology 1996; 137(7): 2968-78.
101. Goke R, Larsen PJ, Mikkelsen JD, Sheikh SP. Distribution of GLP-1 binding sites in the rat brain: evidence that exendin-4 is a ligand of brain GLP-1 binding sites. Eur J Neurosci 1995; 7(11): 2294-300.
102. Nakagawa A, Satake H, Nakabayashi H, Nishizawa M, Furuya K, Nakano S, et al. Receptor gene expression of glucagon-like peptide-1, but not glucose-dependent insulinotropic polypeptide, in rat nodose ganglion cells. Auton Neurosci 2004; 110(1): 36-43.
103. Valverde I, Merida E, Delgado E, Trapote MA, Villanueva-Penacarrillo ML. Presence and characterization of glucagon-like peptide-1(7-36) amide receptors in solubilized membranes of rat adipose tissue. Endocrinology 1993; 132(1): 75-9.
104. Sandhu H, Wiesenthal SR, MacDonald PE, McCall RH, Tchipashvili V, Rashid S, et al. Glucagon-like peptide 1 increases insulin sensitivity in depancreatized dogs. Diabetes 1999; 48(5): 1045-53.
105. Delgado E, Luque MA, Alcantara A, Trapote MA, Clemente F, Galera C, et al. Glucagon-like peptide-1 binding to rat skeletal muscle. Peptides 1995; 16(2): 225-9.
106. Luque MA, Gonzalez N, Marquez L, Acitores A, Redondo A, Morales M, et al. Glucagon-like peptide-1 (GLP-1) and glucose metabolism in human myocytes. J Endocrinol 2002; 173(3): 465-73.
107. Villanueva-Penacarrillo ML, Delgado E, Trapote MA, Alcantara A, Clemente F, Luque MA, et al. Glucagon-like peptide-1 binding to rat hepatic membranes. J Endocrinol 1995; 146(1): 183-9.
108. Alcantara AI, Morales M, Delgado E, Lopez-Delgado MI, Clemente F, Luque MA, et al. Exendin-4 agonist and exendin(9-39)amide antagonist of the GLP-1(7-36)amide effects in liver and muscle. Arch Biochem Biophys 1997; 341(1): 1-7.
109. Heller RS, Kieffer TJ, Habener JF. Insulinotropic glucagon-like peptide I receptor expression in glucagon-producing alpha-cells of the rat endocrine pancreas. Diabetes 1997; 46(5): 785-91.
110. Moens K, Heimberg H, Flamez D, Huypens P, Quartier E, Ling Z, et al. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 1996; 45(2): 257-61.
111. Kang G, Joseph JW, Chepurny OG, Monaco M, Wheeler MB, Bos JL, et al. Epac-selective cAMP analog 8-pCPT-2′-O-Me-cAMP as a stimulus for Ca2+-induced Ca2+ release and exocytosis in pancreatic beta-cells. J Biol Chem 2003; 278(10): 8279-85.
112. Gromada J, Holst JJ, Rorsman P. Cellular regulation of islet hormone secretion by the incretin hormone glucagon-like peptide 1. Pflugers Arch 1998; 435(5): 583-94.
113. MacDonald PE, Wang X, Xia F, El-kholy W, Targonsky ED, Tsushima RG, et al. Antagonism of rat beta-cell voltage-dependent K+ currents by exendin 4 requires dual activation of the cAMP/protein kinase A and phosphatidylinositol 3-kinase signaling pathways. J Biol Chem 2003; 278(52): 52446-53.
114. Flamez D, Gilon P, Moens K, Van Breusegem A, Delmeire D, Scrocchi LA, et al. Altered cAMP and Ca2+ signaling in mouse pancreatic islets with glucagon-like peptide-1 receptor null phenotype. Diabetes 1999; 48(10): 1979-86.
115. Gromada J, Bokvist K, Ding WG, Holst JJ, Nielsen JH, Rorsman P. Glucagon-like peptide 1 (7-36) amide stimulates exocytosis in human pancreatic beta-cells by both proximal and distal regulatory steps in stimulus-secretion coupling. Diabetes 1998; 47(1): 57-65.
116. Larsen PJ, Tang-Christensen M, Jessop DS. Central administration of glucagon-like peptide-1 activates hypothalamic neuroendocrine neurons in the rat. Endocrinology 1997; 138(10): 4445-55.
117. Vrang N, Phifer CB, Corkern MM, Berthoud HR. Gastric distension induces c-Fos in medullary GLP-1/2-containing neurons. Am J Physiol Regul Integr Comp Physiol 2003; 285(2): R470-8.
118. Drucker DJ. Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. Mol Endocrinol 2003; 17(2): 161-71.
119. Wang Q, Li L, Xu E, Wong V, Rhodes C, Brubaker PL. Glucagon-like peptide-1 regulates proliferation and apoptosis via activation of protein kinase B in pancreatic INS-1 beta cells. Diabetologia 2004; 47(3): 478-87.
120. Urusova IA, Farilla L, Hui H, D'Amico E, Perfetti R. GLP-1 inhibition of pancreatic islet cell apoptosis. Trends Endocrinol Metab 2004; 15(1): 27-33.
121. Scrocchi LA, Brown TJ, MaClusky N, Brubaker PL, Auerbach AB, Joyner AL, et al. Glucose intolerance but normal satiety in mice with a null mutation in the glucagon-like peptide 1 receptor gene. Nat Med 1996; 2(11): 1254-8.
122. Ling Z, Wu D, Zambre Y, Flamez D, Drucker DJ, Pipeleers DG, et al. Glucagon-like peptide 1 receptor signaling influences topography of islet cells in mice. Virchows Arch 2001; 438(4): 382-7.
123. Kjems LL, Holst JJ, Volund A, Madsbad S. The influence of GLP-1 on glucose-stimulated insulin secretion: effects on beta-cell sensitivity in type 2 and nondiabetic subjects. Diabetes 2003; 52(2): 380-6.
124. Wang Y, Egan JM, Raygada M, Nadiv O, Roth J, Montrose-Rafizadeh C. Glucagon-like peptide-1 affects gene transcription and messenger ribonucleic acid stability of components of the insulin secretory system in RIN 1046-38 cells. Endocrinology 1995; 136(11): 4910-7.
125. Holst JJ. Therapy of type 2 diabetes mellitus based on the actions of glucagon-like peptide-1. Diabetes Metab Res Rev 2002; 18(6): 430-41.
126. Deacon CF. Therapeutic strategies based on glucagon-like Peptide 1. Diabetes 2004; 53(9): 2181-9.
127. Toft-Nielsen MB, Damholt MB, Madsbad S, Hilsted LM, Hughes TE, Michelsen BK, et al. Determinants of the impaired secretion of glucagon-like peptide-1 in type 2 diabetic patients. J Clin Endocrinol Metab 2001; 86(8): 3717-23.
128. Zander M, Madsbad S, Madsen JL, Holst JJ. Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and beta-cell function in type 2 diabetes: a parallel-group study. Lancet 2002; 359(9309): 824-30.
129. Nauck MA, Holst JJ, Willms B. Glucagon-like peptide 1 and its potential in the treatment of non-insulin-dependent diabetes mellitus. Horm Metab Res 1997; 29(9): 411-6.
130. Zander M, Taskiran M, Toft-Nielsen MB, Madsbad S, Holst JJ. Additive glucose-lowering effects of glucagon-like peptide-1 and metformin in type 2 diabetes. Diabetes Care 2001; 24(4): 720-5.
131. Zander M, Christiansen A, Madsbad S, Juul Holst J. Additive effects of glucagon-like Peptide 1 and pioglitazone in patients with type 2 diabetes. Diabetes Care 2004; 27(8): 1910-4.
132. Gutniak MK, Juntti-Berggren L, Hellstrom PM, Guenifi A, Holst JJ, Efendic S. Glucagon-like peptide I enhances the insulinotropic effect of glibenclamide in NIDDM patients and in the perfused rat pancreas. Diabetes Care 1996; 19(8): 857-63.
133. Fineman MS, Bicsak TA, Shen LZ, Taylor K, Gaines E, Varns A, et al. Effect on glycemic control of exenatide (synthetic exendin-4) additive to existing metformin and/or sulfonylurea treatment in patients with type 2 diabetes. Diabetes Care 2003; 26(8): 2370-7.
134. Meneilly GS, McIntosh CH, Pederson RA, Habener JF, Ehlers MR, Egan JM, et al. Effect of glucagon-like peptide 1 (7-36 amide) on insulin-mediated glucose uptake in patients with type 1 diabetes. Diabetes Care 2003; 26(3): 837-42.
135. Behme MT, Dupre J, McDonald TJ. Glucagon-like peptide 1 improved glycemic control in type 1 diabetes. BMC Endocr Disord 2003; 3(1): 3.
136. Dupre J, Behme MT, McDonald TJ. Exendin-4 normalized postcibal glycemic excursions in type 1 diabetes. J Clin Endocrinol Metab 2004; 89(7): 3469-73.
137. Turton MD, O'Shea D, Gunn I, Beak SA, Edwards CM, Meeran K, et al. A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 1996; 379(6560): 69-72.
138. Tang-Christensen M, Larsen PJ, Goke R, Fink-Jensen A, Jessop DS, Moller M, et al. Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 1996; 271(4 Pt 2): R848-56.
139. Seeley RJ, Blake K, Rushing PA, Benoit S, Eng J, Woods SC, et al. The role of CNS glucagon-like peptide-1 (7-36) amide receptors in mediating the visceral illness effects of lithium chloride. J Neurosci 2000; 20(4): 1616-21.
140. Kinzig KP, D'Alessio DA, Herman JP, Sakai RR, Vahl TP, Figueiredo HF, et al. CNS glucagon-like peptide-1 receptors mediate endocrine and anxiety responses to interoceptive and psychogenic stressors. J Neurosci 2003; 23(15): 6163-70.
141. Kastin AJ, Akerstrom V, Pan W. Interactions of glucagon-like peptide-1 (GLP-1) with the blood-brain barrier. J Mol Neurosci 2002; 18(1-2): 7-14.
142. Kastin AJ, Akerstrom V. Entry of exendin-4 into brain is rapid but may be limited at high doses. Int J Obes Relat Metab Disord 2003; 27(3): 313-8.
143. Baggio LL, Huang Q, Brown TJ, Drucker DJ. A recombinant human GLP-1-albumin protein (Albugon) mimics peptidergic activation of GLP-1R-dependent pathways coupled to satiety, gastrointestinal motility, and glucose homeostatis. Diabetes 2004; 53(9): 2492-500.
144. Gutzwiller JP, Drewe J, Goke B, Schmidt H, Rohrer B, Lareida J, et al. Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitus type 2. Am J Physiol 1999; 276(5 Pt 2): R1541-4.
145. Naslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, et al. Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 1999; 23(3): 304-11.
146. Flint A, Raben A, Astrup A, Holst JJ. Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 1998; 101(3): 515-20.
147. Naslund E, King N, Mansten S, Adner N, Holst JJ, Gutniak M, et al. Prandial subcutaneous injections of glucagon-like peptide-1 cause weight loss in obese human subjects. Br J Nutr 2004; 91(3): 439-46.
148. Perry T, Lahiri DK, Chen D, Zhou J, Shaw KT, Egan JM, et al. A novel neurotrophic property of glucagon-like peptide 1: a promoter of nerve growth factor-mediated differentiation in PC12 cells. J Pharmacol Exp Ther 2002; 300(3): 958-66.
149. Perry T, Lahiri DK, Sambamurti K, Chen D, Mattson MP, Egan JM, et al. Glucagon-like peptide-1 decreases endogenous amyloid-beta peptide (Abeta) levels and protects hippocampal neurons from death induced by Abeta and iron. J Neurosci Res 2003; 72(5): 603-12.
150. Perry TA, Greig NH. A new Alzheimer's disease interventive strategy: GLP-1. Curr Drug Targets 2004; 5(6): 565-71.
151. During MJ, Cao L, Zuzga DS, Francis JS, Fitzsimons HL, Jiao X, et al. Glucagon-like peptide-1 receptor is involved in learning and neuroprotection. Nat Med 2003; 9(9): 1173-9.
152. Barragan JM, Rodriguez RE, Blazquez E. Changes in arterial blood pressure and heart rate induced by glucagon-like peptide-1-(7-36) amide in rats. Am J Physiol 1994; 266(3 Pt 1): E459-66.
153. Baggio L, Adatia F, Bock T, Brubaker PL, Drucker DJ. Sustained expression of exendin-4 does not perturb glucose homeostasis, beta-cell mass, or food intake in metallothionein-preproexendin transgenic mice. J Biol Chem 2000; 275(44): 34471-7.
154. Yamamoto H, Lee CE, Marcus JN, Williams TD, Overton JM, Lopez ME, et al. Glucagon-like peptide-1 receptor stimulation increases blood pressure and heart rate and activates autonomic regulatory neurons. J Clin Invest 2002; 110(1): 43-52.
155. Gros R, You X, Baggio LL, Kabir MG, Sadi AM, Mungrue IN, et al. Cardiac function in mice lacking the glucagon-like peptide-1 receptor. Endocrinology 2003; 144(6): 2242-52.
156. Vila Petroff MG, Egan JM, Wang X, Sollott SJ. Glucagon-like peptide-1 increases cAMP but fails to augment contraction in adult rat cardiac myocytes. Circ Res 2001; 89(5): 445-52.
157. Yamamoto H, Kishi T, Lee CE, Choi BJ, Fang H, Hollenberg AN, et al. Glucagon-like peptide-1-responsive catecholamine neurons in the area postrema link peripheral glucagon-like peptide-1 with central autonomic control sites. J Neurosci 2003; 23(7): 2939-46.
158. Isbil-Buyukcoskun N, Gulec G. Effects of intracerebroventricularly injected glucagon-like peptide-1 on cardiovascular parameters; role of central cholinergic system and vasopressin. Regul Pept 2004; 118(1-2): 33-8.
159. Nikolaidis LA, Elahi D, Hentosz T, Doverspike A, Huerbin R, Zourelias L, et al. Recombinant glucagon-like peptide-1 increases myocardial glucose uptake and improves left ventricular performance in conscious dogs with pacing-induced dilated cardiomyopathy. Circulation 2004; 110(8): 955-61.
160. Yu M, Moreno C, Hoagland KM, Dahly A, Ditter K, Mistry M, et al. Antihypertensive effect of glucagon-like peptide 1 in Dahl salt-sensitive rats. J Hypertens 2003; 21(6): 1125-35.
161. Moreno C, Mistry M, Roman RJ. Renal effects of glucagon-like peptide in rats. Eur J Pharmacol 2002; 434(3): 163-7.
162. Gutzwiller JP, Tschopp S, Bock A, Zehnder CE, Huber AR, Kreyenbuehl M, et al. Glucagon-like peptide 1 induces natriuresis in healthy subjects and in insulin-resistant obese men. J Clin Endocrinol Metab 2004; 89(6): 3055-61.
163. Nikolaidis LA, Mankad S, Sokos GG, Miske G, Shah A, Elahi D, et al. Effects of glucagon-like peptide-1 in patients with acute myocardial infarction and left ventricular dysfunction after successful reperfusion. Circulation 2004; 109(8): 962-5.
164. Wettergren A, Wojdemann M, Holst JJ. The inhibitory effect of glucagon-like peptide-1 (7-36)amide on antral motility is antagonized by its N-terminally truncated primary metabolite GLP-1 (9-36)amide. Peptides 1998; 19(5): 877-82.
165. Deacon CF, Plamboeck A, Moller S, Holst JJ. GLP-1-(9-36) amide reduces blood glucose in anesthetized pigs by a mechanism that does not involve insulin secretion. Am J Physiol Endocrinol Metab 2002; 282(4): E873-9.
166. Vahl TP, Paty BW, Fuller BD, Prigeon RL, D'Alessio DA. Effects of GLP-1-(7-36)NH2, GLP-1-(7-37), and GLP-1- (9-36)NH2 on intravenous glucose tolerance and glucose-induced insulin secretion in healthy humans. J Clin Endocrinol Metab 2003; 88(4): 1772-9.
167. Jeppesen PB, Hartmann B, Thulesen J, Graff J, Lohmann J, Hansen BS, et al. Glucagon-like peptide 2 improves nutrient absorption and nutritional status in short-bowel patients with no colon. Gastroenterology 2001; 120(4): 806-15.
168. Eng J, Kleinman WA, Singh L, Singh G, Raufman JP. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. J Biol Chem 1992; 267(11): 7402-5.
169. Goke R, Fehmann HC, Linn T, Schmidt H, Krause M, Eng J, et al. Exendin-4 is a high potency agonist and truncated exendin-(9-39)-amide an antagonist at the glucagon-like peptide 1-(7-36)-amide receptor of insulin-secreting beta-cells. J Biol Chem 1993; 268(26): 19650-5.
170. Xu G, Stoffers DA, Habener JF, Bonner-Weir S. Exendin-4 stimulates both beta-cell replication and neogenesis, resulting in increased beta-cell mass and improved glucose tolerance in diabetic rats. Diabetes 1999; 48(12): 2270-6.
171. Nielsen LL, Young AA, Parkes DG. Pharmacology of exenatide (synthetic exendin-4): a potential therapeutic for improved glycemic control of type 2 diabetes. Regul Pept 2004; 117(2): 77-88.
172. Knudsen LB. Glucagon-like peptide-1: the basis of a new class of treatment for type 2 diabetes. J Med Chem 2004; 47(17): 4128-34.
173. Doyle ME, Theodorakis MJ, Holloway HW, Bernier M, Greig NH, Egan JM. The importance of the nine-amino acid C-terminal sequence of exendin-4 for binding to the GLP-1 receptor and for biological activity. Regul Pept 2003; 114(2-3): 153-8.
174. Lopez de Maturana R, Willshaw A, Kuntzsch A, Rudolph R, Donnelly D. The isolated N-terminal domain of the glucagon-like peptide-1 (GLP-1) receptor binds exendin peptides with much higher affinity than GLP-1. J Biol Chem 2003; 278(12): 10195-200.
175. Green BD, Gault VA, Irwin N, Mooney MH, Bailey CJ, Harriott P, et al. Metabolic stability, receptor binding, cAMP generation, insulin secretion and antihyperglycaemic activity of novel N-terminal Glu9-substituted analogues of glucagon-like peptide-1. Biol Chem 2003; 384(12): 1543-51.
176. Green BD, Gault VA, Mooney MH, Irwin N, Bailey CJ, Harriott P, et al. Novel dipeptidyl peptidase IV resistant analogues of glucagon-like peptide-1(7-36)amide have preserved biological activities in vitro conferring improved glucose-lowering action in vivo. J Mol Endocrinol 2003; 31(3): 529-40.
177. Green BD, Mooney MH, Gault VA, Irwin N, Bailey CJ, Harriott P, et al. N-terminal His(7)-modification of glucagon-like peptide-1(7-36) amide generates dipeptidyl peptidase IV-stable analogues with potent antihyperglycaemic activity. J Endocrinol 2004; 180(3): 379-88.
178. Kolterman OG, Buse JB, Fineman MS, Gaines E, Heintz S, Bicsak TA, et al. Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab 2003; 88(7): 3082-9.
179. O'Harte FP, Mooney MH, Lawlor A, Flatt PR. N-terminally modified glucagon-like peptide-1(7-36) amide exhibits resistance to enzymatic degradation while maintaining its antihyperglycaemic activity in vivo. Biochim Biophys Acta 2000; 1474(1): 13-22.
180. Green BD, Gault VA, Mooney MH, Irwin N, Harriott P, Greer B, et al. Degradation, receptor binding, insulin secreting and antihyperglycaemic actions of palmitate-derivatised native and Ala8- substituted GLP-1 analogues. Biol Chem 2004; 385(2): 169-77.
181. Agerso H, Jensen LB, Elbrond B, Rolan P, Zdravkovic M. The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men. Diabetologia 2002; 45(2): 195-202.
182. Elbrond B, Jakobsen G, Larsen S, Agerso H, Jensen LB, Rolan P, et al. Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. Diabetes Care 2002; 25(8): 1398-404.
183. Degn KB, Juhl CB, Sturis J, Jakobsen G, Brock B, Chandramouli V, et al. One week's treatment with the long-acting glucagon-like peptide 1 derivative liraglutide (NN2211) markedly improves 24-h glycemia and alpha- and beta-cell function and reduces endogenous glucose release in patients with type 2 diabetes. Diabetes 2004; 53(5): 1187-94.
184. Harder H, Nielsen L, Thi TD, Astrup A. The Effect of Liraglutide, a Long-Acting Glucagon-Like Peptide 1 Derivative, on Glycemic Control, Body Composition, and 24-h Energy Expenditure in Patients With Type 2 Diabetes. Diabetes Care 2004; 27(8): 1915-21.
185. Madsbad S, Schmitz O, Ranstam J, Jakobsen G, Matthews DR. Improved glycemic control with no weight increase in patients with type 2 diabetes after once-daily treatment with the long-acting glucagon-like peptide 1 analog liraglutide (NN2211): a 12-week, double-blind, randomized, controlled trial. Diabetes Care 2004; 27(6): 1335-42.
186. Giannoukakis N. CJC-1131. ConjuChem. Curr Opin Investig Drugs 2003; 4(10): 1245-9.
187. Kim JG, Baggio LL, Bridon DP, Castaigne JP, Robitaille MF, Jette L, et al. Development and characterization of a glucagon-like peptide 1-albumin conjugate: the ability to activate the glucagon-like peptide 1 receptor in vivo. Diabetes 2003; 52(3): 751-9.
188. Wojdemann M, Wettergren A, Hartmann B, Holst JJ. Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 1998; 33(8): 828-32.
189. Wojdemann M, Wettergren A, Hartmann B, Hilsted L, Holst JJ. Inhibition of sham feeding-stimulated human gastric acid secretion by glucagon-like peptide-2. J Clin Endocrinol Metab 1999; 84(7): 2513-7.
190. Nagell CF, Wettergren A, Pedersen JF, Mortensen D, Holst JJ. Glucagon-like peptide-2 inhibits antral emptying in man, but is not as potent as glucagon-like peptide-1. Scand J Gastroenterol 2004; 39(4): 353-8.
191. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon- like peptide-2. Am J Physiol 1997; 272(6 Pt 1): E1050-8.
192. Kato Y, Yu D, Schwartz MZ. Glucagonlike peptide-2 enhances small intestinal absorptive function and mucosal mass in vivo. J Pediatr Surg 1999; 34(1): 18-20; discussion 20-1.
193. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut 2000; 47(1): 112-9.
194. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci USA 1996; 93(15): 7911-6.
195. Estall JL, Drucker DJ. Dual regulation of cell proliferation and survival via activation of glucagon-like peptide-2 receptor signaling. J Nutr 2003; 133(11): 3708-11.
196. Drucker DJ. Gut adaptation and the glucagon-like peptides. Gut 2002; 50(3): 428-35.
197. Tang-Christensen M, Larsen PJ, Thulesen J, Romer J, Vrang N. The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 2000; 6(7): 802-7.
198. Lovshin J, Estall J, Yusta B, Brown TJ, Drucker DJ. Glucagon-like peptide (GLP)-2 action in the murine central nervous system is enhanced by elimination of GLP-1 receptor signaling. J Biol Chem 2001; 276(24): 21489-99.
199. Schmidt PT, Naslund E, Gryback P, Jacobsson H, Hartmann B, Holst JJ, et al. Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 2003; 116(1-3): 21-5.
200. Sorensen LB, Flint A, Raben A, Hartmann B, Holst JJ, Astrup A. No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes Relat Metab Disord 2003; 27(4): 450-6.
201. Munroe DG, Gupta AK, Kooshesh F, Vyas TB, Rizkalla G, Wang H, et al. Prototypic G protein-coupled receptor for the intestinotrophic factor glucagon-like peptide 2. Proc Natl Acad Sci USA 1999; 96(4): 1569-73.
202. Yusta B, Huang L, Munroe D, Wolff G, Fantaske R, Sharma S, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology 2000; 119(3): 744-55.
203. Lovshin JA, Huang Q, Seaberg R, Brubaker PL, Drucker DJ. Extrahypothalamic expression of the glucagon-like peptide-2 receptor is coupled to reduction of glutamate-induced cell death in cultured hippocampal cells. Endocrinology 2004; 145(7): 3495-506.
204. Bjerknes M, Cheng H. Modulation of specific intestinal epithelial progenitors by enteric neurons. Proc Natl Acad Sci USA 2001; 98(22): 12497-502.
205. DaCambra MP, Yusta B, Sumner-Smith M, Crivici A, Drucker DJ, Brubaker PL. Structural determinants for activity of glucagon-like peptide-2. Biochemistry 2000; 39(30): 8888-94.
206. Yusta B, Somwar R, Wang F, Munroe D, Grinstein S, Klip A, et al. Identification of glucagon-like peptide-2 (GLP-2)-activated signaling pathways in baby hamster kidney fibroblasts expressing the rat GLP-2 receptor. J Biol Chem 1999; 274(43): 30459-67.
207. Walsh NA, Yusta B, DaCambra MP, Anini Y, Drucker DJ, Brubaker PL. Glucagon-like peptide-2 receptor activation in the rat intestinal mucosa. Endocrinology 2003; 144(10): 4385-92.
208. Guan X, Stoll B, Lu X, Tappenden KA, Holst JJ, Hartmann B, et al. GLP-2-mediated up-regulation of intestinal blood flow and glucose uptake is nitric oxide-dependent in TPN-fed piglets 1. Gastroenterology 2003; 125(1): 136-47.
209. Yusta B, Boushey RP, Drucker DJ. The glucagon-like peptide-2 receptor mediates direct inhibition of cellular apoptosis via a cAMP-dependent protein kinase-independent pathway. J Biol Chem 2000; 275(45): 35345-52.
210. Yusta B, Estall J, Drucker DJ. Glucagon-like peptide-2 receptor activation engages bad and glycogen synthase kinase-3 in a protein kinase A-dependent manner and prevents apoptosis following inhibition of phosphatidylinositol 3-kinase. J Biol Chem 2002; 277(28): 24896-906.
211. Jasleen J, Ashley SW, Shimoda N, Zinner MJ, Whang EE. Glucagon-like peptide 2 stimulates intestinal epithelial proliferation in vitro. Dig Dis Sci 2002; 47(5): 1135-40.
212. Velazquez E, Ruiz-Albusac JM, Blazquez E. Glucagon-like peptide-2 stimulates the proliferation of cultured rat astrocytes. Eur J Biochem 2003; 270(14): 3001-9.
213. Rocha FG, Shen KR, Jasleen J, Tavakkolizadeh A, Zinner MJ, Whang EE, et al. Glucagon-like peptide-2: Divergent signaling pathways(1). J Surg Res 2004; 121(1): 5-12.
214. Bulut K, Meier JJ, Ansorge N, Felderbauer P, Schmitz F, Hoffmann P, et al. Glucagon-like peptide 2 improves intestinal wound healing through induction of epithelial cell migration in vitro-evidence for a TGF-beta-mediated effect. Regul Pept 2004; 121(1-3): 137-43.
215. Stevens FM, Flanagan RW, O'Gorman D, Buchanan KD. Glucagonoma syndrome demonstrating giant duodenal villi. Gut 1984; 25(7): 784-91.
216. Thulesen J, Knudsen LB, Hartmann B, Hastrup S, Kissow H, Jeppesen PB, et al. The truncated metabolite GLP-2 (3-33) interacts with the GLP-2 receptor as a partial agonist. Regul Pept 2002; 103(1): 9-15.
217. Drucker DJ, Shi Q, Crivici A, Sumner-Smith M, Tavares W, Hill M, et al. Regulation of the biological activity of glucagon-like peptide 2 in vivo by dipeptidyl peptidase IV. Nat Biotechnol 1997; 15(7): 673-7.
218. Chance WT, Foley-Nelson T, Thomas I, Balasubramaniam A. Prevention of parenteral nutrition-induced gut hypoplasia by coinfusion of glucagon-like peptide-2. Am J Physiol 1997; 273(2 Pt 1): G559-63.
219. Chance WT, Sheriff S, Foley-Nelson T, Thomas I, Balasubramaniam A. Maintaining gut integrity during parenteral nutrition of tumor-bearing rats: effects of glucagon-like peptide 2. Nutr Cancer 2000; 37(2): 215-22.
220. Burrin DG, Stoll B, Jiang R, Petersen Y, Elnif J, Buddington RK, et al. GLP-2 stimulates intestinal growth in premature TPN-fed pigs by suppressing proteolysis and apoptosis. Am J Physiol Gastrointest Liver Physiol 2000; 279(6): G1249-56.
221. Martin GR, Wallace LE, Sigalet DL. Glucagon-like peptide-2 induces intestinal adaptation in parenterally fed rats with short bowel syndrome. Am J Physiol Gastrointest Liver Physiol 2004; 286(6): G964-72.
222. Kouris GJ, Liu Q, Rossi H, Djuricin G, Gattuso P, Nathan C, et al. The effect of glucagon-like peptide 2 on intestinal permeability and bacterial translocation in acute necrotizing pancreatitis. Am J Surg 2001; 181(6): 571-5.
223. Chance WT, Sheriff S, McCarter F, Ogle C. Glucagon-like peptide-2 stimulates gut mucosal growth and immune response in burned rats. J Burn Care Rehabil 2001; 22(2): 136-43.
224. Scott RB, Kirk D, MacNaughton WK, Meddings JB. GLP-2 augments the adaptive response to massive intestinal resection in rat. Am J Physiol 1998; 275(5 Pt 1): G911-21.
225. Rajeevprasad R, Alavi K, Schwartz MZ. Glucagonlike peptide-2 analogue enhances intestinal mucosal mass and absorptive function after ischemia-reperfusion injury. J Pediatr Surg 2000; 35(11): 1537-9.
226. Drucker DJ, Yusta B, Boushey RP, DeForest L, Brubaker PL. Human [Gly2]GLP-2 reduces the severity of colonic injury in a murine model of experimental colitis. Am J Physiol 1999; 276(1 Pt 1): G79-91.
227. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide 2 decreases mortality and reduces the severity of indomethacin-induced murine enteritis. Am J Physiol 1999; 277(5 Pt 1): E937-47.
228. Alavi K, Schwartz MZ, Palazzo JP, Prasad R. Treatmen of inflammatory bowel disease in a rodent model with the intestinal growth factor glucagon-like peptide-2. J Pediatr Surg 2000; 35(6): 847-51.
229. L'Heureux MC, Brubaker PL. Glucagon-like peptide-2 and common therapeutics in a murine model of ulcerative colitis. J Pharmacol Exp Ther 2003; 306(1): 347-54.
230. Arthur GL, Schwartz MZ, Kuenzler KA, Birbe R. Glucagonlike peptide-2 analogue: a possible new approach in the management of inflammatory bowel disease. J Pediatr Surg 2004; 39(3): 448-52; discussion 448-52.
231. Cameron HL, Yang PC, Perdue MH. Glucagon-like peptide-2-enhanced barrier function reduces pathophysiology in a model of food allergy. Am J Physiol Gastrointest Liver Physiol 2003; 284(6): G905-12.
232. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res 2001; 61(2): 687-93.
233. Yamazaki K, Yasuda N, Inoue T, Nagakura T, Kira K, Saeki T, et al. The combination of metformin and a dipeptidyl peptidase IV inhibitor prevents 5-fluorouracil-induced reduction of small intestine weight. Eur J Pharmacol 2004; 488(1-3): 213-8.
234. Thulesen J, Hartmann B, Hare KJ, Kissow H, Orskov C, Holst JJ, et al. Glucagon-like peptide 2 (GLP-2) accelerates the growth of colonic neoplasms in mice. Gut 2004; 53(8): 1145-50.
235. Haderslev KV, Jeppesen PB, Hartmann B, Thulesen J, Sorensen HA, Graff J, et al. Short-term administration of glucagon-like peptide-2. Effects on bone mineral density and markers of bone turnover in short-bowel patients with no colon. Scand J Gastroenterol 2002; 37(4): 392-8.
236. Henriksen DB, Alexandersen P, Bjarnason NH, Vilsboll T, Hartmann B, Henriksen EE, et al. Role of gastrointestinal hormones in postprandial reduction of bone resorption. J Bone Miner Res 2003; 18(12): 2180-9.
237. Henriksen DB, Alexandersen P, Byrjalsen I, Hartmann B, Bone HG, Christiansen C, et al. Reduction of nocturnal rise in bone resorption by subcutaneous GLP-2. Bone 2004; 34(1): 140-7.
238. Aytac U, Dang NH. CD26/dipeptidyl peptidase IV: a regulator of immune function and a potential molecular target for therapy. Curr Drug Targets Immune Endocr Metabol Disord 2004; 4(1): 11-8.
239. Marguet D, Baggio L, Kobayashi T, Bernard AM, Pierres M, Nielsen PF, et al. Enhanced insulin secretion and improved glucose tolerance in mice lacking CD26. Proc Natl Acad Sci USA 2000; 97(12): 6874-9.
240. Yan S, Marguet D, Dobers J, Reutter W, Fan H. Deficiency of CD26 results in a change of cytokine and immunoglobulin secretion after stimulation by pokeweed mitogen. Eur J Immunol 2003; 33(6): 1519-27.
241. Pederson RA, White HA, Schlenzig D, Pauly RP, McIntosh CH, Demuth HU. Improved glucose tolerance in Zucker fatty rats by oral administration of the dipeptidyl peptidase IV inhibitor isoleucine thiazolidide. Diabetes 1998; 47(8): 1253-8.
242. Ahren B, Holst JJ, Martensson H, Balkan B. Improved glucose tolerance and insulin secretion by inhibition of dipeptidyl peptidase IV in mice. Eur J Pharmacol 2000; 404(1-2): 239-45.
243. Balkan B, Kwasnik L, Miserendino R, Holst JJ, Li X. Inhibition of dipeptidyl peptidase IV with NVP-DPP728 increases plasma GLP-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 1999; 42(11): 1324-31.
244. Deacon CF, Danielsen P, Klarskov L, Olesen M, Holst JJ. Dipeptidyl peptidase IV inhibition reduces the degradation and clearance of GIP and potentiates its insulinotropic and antihyperglycemic effects in anesthetized pigs. Diabetes 2001; 50(7): 1588-97.
245. Ahren B, Landin-Olsson M, Jansson PA, Svensson M, Holmes D, Schweizer A. Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 2004; 89(5): 2078-84.
246. Drucker DJ. Therapeutic potential of dipeptidyl peptidase IV inhibitors for the treatment of type 2 diabetes. Expert Opin Investig Drugs 2003; 12(1): 87-100.
247. Holst JJ. Treatment of Type 2 diabetes mellitus with agonists of the GLP-1 receptor or DPP-IV inhibitors. Expert Opin Emerg Drugs 2004; 9(1): 155-166.
248. Ferguson SS. Evolving concepts in G protein-coupled receptor endocytosis: the role in receptor desensitization and signaling. Pharmacol Rev 2001; 53(1): 1-24.
249. Premont RT, Iyengar R. Glucagon-induced desensitization of adenylyl cyclase in primary cultures of chick hepatocytes. Evidence for multiple pathways. J Biol Chem 1988; 263(31): 16087-95
250. Savage A, Zeng L, Houslay MD. A role for protein kinase C-mediated phosphorylation in eliciting glucagon desensitization in rat hepatocytes. Biochem J 1995; 307(Pt 1): 281-5.
251. Widmann C, Dolci W, Thorens B. Agonist-induced internalization and recycling of the glucagon-like peptide-1 receptor in transfected fibroblasts and in insulinomas. Biochem J 1995; 310(Pt 1): 203-14.
252. Widmann C, Dolci W, Thorens B. Heterologous desensitization of the glucagon-like peptide-1 receptor by phorbol esters requires phosphorylation of the cytoplasmic tail at four different sites. J Biol Chem 1996; 271(33): 19957-63.
253. Widmann C, Dolci W, Thorens B. Desensitization and phosphorylation of the glucagon-like peptide-1 (GLP- 1) receptor by GLP-1 and 4-phorbol 12-myristate 13-acetate. Mol Endocrinol 1996; 10(1): 62-75.
254. Widmann C, Dolci W, Thorens B. Internalization and homologous desensitization of the GLP-1 receptor depend on phosphorylation of the receptor carboxyl tail at the same three sites. Mol Endocrinol 1997; 11(8): 1094-102.
255. Estall JL, Yusta B, Drucker DJ. Lipid Raft-dependent Glucagon-like Peptide-2 Receptor Trafficking Occurs Independently of Agonist-induced Desensitization. Mol Biol Cell 2004; 15(8): 3673-87.
256. 14C]-Labelling of the GLP-1-(7-37)derivative NN2211. Journal of Labelled Compounds and Radiopharmaceuticals 2003; 46(6): 499-510.
257. Dogrukol-Ak D, Tore F, Tuncel N. Passage of VIP/PACAP/secretin family across the blood-brain barrier: therapeutic effects. Curr Pharm Des 2004; 10(12): 1325-40.
258. Gotthardt M, Boermann OC, Behr TM, Behe MP, Oyen WJ. Development and clinical application of peptide-based radiopharmaceuticals. Curr Pharm Des 2004; 10(24): 2951-63.
259. Green BD, Gault VA, O'harte FP, Flatt PR. Structurally modified analogues of glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP) as future antidiabetic agents. Curr Pharm Des 2004; 10(29): 3651-62.